Inhaler devices in asthma and COPD patients – A prospective cross-sectional study on inhaler preferences and error rates

Schreiber, Jens; Sonnenburg, Tina; Luecke, Eva

doi:10.21203/rs.3.rs-29319/v2

Cited by 8 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This inhaler attribute in combination with an easy cleaning procedure is also an important factor to ensure patients' handling satisfaction 25 . Today it is well accepted, that therapeutic success of inhalation therapy depends more than expected on a patient's perception, preference, and satisfaction with the inhaler 26,27 because higher satisfaction with the device seems to contribute markedly to an increased treatment adherence in COPD patients 3,[28][29][30] .…”

Section: Discussionmentioning

confidence: 99%

Switching COPD patients from the disposable to the new reusable Respimat soft mist inhaler: a real-world study from Switzerland

Tschacher¹,

Cadus²,

Schildge

et al. 2021

Current Medical Research and Opinion

View full text Add to dashboard Cite

Objective: The aims of the survey were to assess first experiences of Swiss COPD patients switching from the disposable to the new reusable Respimat inhaler, and to evaluate physicians and patients views of the new training material. Methods: Patients with a confirmed diagnosis of COPD using a disposable Respimat inhaler for at least three months were included. Patients demographics, COPD stage, current treatment, and comorbidities relevant for the handling of the device were assessed. Further, patients were trained on the reusable Respimat by placebo inhaler, patient brochure, video cards/demo films and SMS reminder service. After at least one cartridge change, patients gave comprehensive feedback on their satisfaction with the reusable Respimat and physicians evaluated the need for re-training. Results: 235 patients participated in the survey. Of these, 37% suffered from comorbidities restricting the handling of the Respimat. 216 (92%) patients had a better overall satisfaction with the reusable than with the disposable Respimat. Dose counter (86%), monthly preparation (81%) and daily handling (77%) were also assessed as better by most of the patients. In 80% of cases, the user ability was stated as better than for the disposable Respimat. Less than 15% of the patients required further training. Placebo inhaler was the mostly preferred training material by both, physicians (in 86% of the patients) and patients (75%). In patients with comorbidities affecting inhaler handling, overall satisfaction was also better in 86% of the patients. Conclusion:The majority of patients were satisfied with the new reusable Respimat device and proper handling could be attained using the provided training material, even in patients with restricting comorbidities.

show abstract

Section: Discussionmentioning

confidence: 99%

Switching COPD patients from the disposable to the new reusable Respimat soft mist inhaler: a real-world study from Switzerland

Tschacher¹,

Cadus²,

Schildge

et al. 2021

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…The lowest number of attempts to achieve error-free use was reported for the Turbuhaler ® and Nexthaler ® devices. Overall, Spiromax ® and Nexthaler ® achieved the best overall ratings and where the devices most preferred by patients [41], 1.02 should be replaced by 1.10. Table 1 lists clinical trials conducted with the Spiromax ® , Turbuhaler ® , and Easyhaler ® devices.…”

Section: Clinical Trials With Spiromax® Turbuhaler® and Easyhaler®mentioning

confidence: 96%

Narrative Review of the Role of Patient-Reported Outcomes and Inhaler Handling Errors in the Control of Asthma and COPD

Gutiérrez¹,

Castro²

2022

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Purpose of Review Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory diseases that remain uncontrolled in many patients, despite the wide range of therapeutic options available. This review analyzes the available clinical evidence on 3 budesonide/formoterol DPI devices, Spiromax®, Turbuhaler®, and Easyhaler®, in terms of patient-reported outcomes (PROs), inhaler errors, and asthma and COPD control. Recent Findings The effectiveness of dry powder inhalers (DPI) depends largely on the device and the patient’s inhaler technique. Equally important are the patient’s perception of the inhaler and adherence. Given the high burden of these diseases, it is important that efforts be made to select the best DPI for each patient and to analyze the impact of these variables to help improve the health and quality of life of our patients. Summary This review provides a comprehensive overview of the present knowledge about PROs, inhaler handling errors, and asthma and COPD control achieved by Spiromax®, Turbuhaler®, and Easyhaler®.

show abstract

“…In a recent study investigating patients' preferences for inhaler device types, 10 different placebo inhaler devices were presented to patients. Despite a high proportion of patients being MDI users, only 14.3% selected MDI as their preferred device, with multidose DPIs proving most popular 51 . This suggests that prescribers should generally offer DPIs or SMIs as the first choice.…”

Section: The Opportunity: Improving Asthma Control and Reducing Carbo...mentioning

confidence: 99%

“…Most patients are able to use a DPI, even during exacerbations 52–54 . Given a choice of modern devices, most patients will select a multidose DPI as their first‐choice inhaler 51 . Some patients (in particular very young children with asthma and elderly patients with severe COPD) may prefer or require an MDI with a spacer.…”

Section: The Opportunity: Improving Asthma Control and Reducing Carbo...mentioning

confidence: 99%

The environmental impact of inhalers for asthma: A green challenge and a golden opportunity

Wilkinson

Woodcock

2021

Brit J Clinical Pharma

View full text Add to dashboard Cite

The propellants in metered‐dose inhalers (MDIs) are powerful greenhouse gases, which account for approximately 13% of the NHS's carbon footprint related to the delivery of care. Most MDI use is in salbutamol relievers in patients with poorly controlled disease. The UK lags behind Europe in this regard, with greater reliance on salbutamol MDI and correspondingly greater greenhouse gas emissions, roughly treble that of our European neighbours. There has been a broad switch towards MDIs in asthma treatment in the UK over the last 20 years to reduce financial costs, such that the treatment for two‐thirds of asthma patients in the UK is dominated by salbutamol MDI. Strategies that replace overuse of reliever MDIs with regimes emphasising inhaled corticosteroids have the potential to improve asthma control alongside significant reductions in greenhouse gas emissions. Real‐world evidence shows that once‐daily long‐acting combination dry‐powder inhalers (DPIs) can improve compliance and asthma control, and reduce the carbon footprint of care. Similarly, maintenance and reliever therapy (MART), which uses combination reliever and inhaled steroids in one device (usually a DPI), can simplify therapy, improve asthma control and reduce greenhouse gas emissions. Both treatment strategies are popular with patients, most of whom would be willing to change treatment to reduce their carbon footprint. By focussing on patients who are currently using high amounts of salbutamol MDI and prioritising inhaled steroids via DPIs, there are golden opportunities to make asthma care in the UK more effective, safer and greener.

show abstract

Inhaler devices in asthma and COPD patients – A prospective cross-sectional study on inhaler preferences and error rates

Cited by 8 publications

References 22 publications

Switching COPD patients from the disposable to the new reusable Respimat soft mist inhaler: a real-world study from Switzerland

Switching COPD patients from the disposable to the new reusable Respimat soft mist inhaler: a real-world study from Switzerland

Narrative Review of the Role of Patient-Reported Outcomes and Inhaler Handling Errors in the Control of Asthma and COPD

The environmental impact of inhalers for asthma: A green challenge and a golden opportunity

Contact Info

Product

Resources

About